<DOC>
	<DOC>NCT02275065</DOC>
	<brief_summary>This study will investigate the short-term antiviral potency, safety, plasma pharmacokinetics (PK), and the PK/pharmacodynamic (PD) relationship (the dose-response relationship) of GS-9883 at multiple doses in antiretroviral (ART) treatment-naive adult subjects and subjects who are ART-experienced but are currently off of ART therapy. Up to 32 participants will be enrolled in the study.</brief_summary>
	<brief_title>Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects</brief_title>
	<detailed_description />
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>No current or prior antiHIV treatment, including antiretroviral medications received for prevention (preexposure prophylaxis [PrEP]), or postexposure prophylaxis (PEP) within 12 weeks of screening Must be between 18 and 65 years of age, inclusive on the date of the screening visit Plasma HIV1 RNA ≥ 10,000 copies/mL but ≤ 400,000 copies/mL at screening CD4+ cell count &gt; 200 cells/mm^3 Anticipated to start HIV1 therapy during the study period Active participation in another study of investigational or approved antiretroviral agents A new AIDSdefining condition diagnosed within the 30 days prior to screening Subjects with positive hepatitis C antibody at screening Chronic hepatitis B virus (HBV) infection Active, serious infections (other than HIV1 infection) requiring parenteral antibiotic or antifungal therapy within 42 days prior to Day 1 (baseline)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>HIV-1 Infected</keyword>
	<keyword>Adults</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>